Tolerx enters collaborative research agreement with Cancer Research Institute

Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) -- a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research -- today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells. TRX518 is the first anti-GITR (glucocorticoid-induced tumor necrosis factor receptor) drug candidate to enter human clinical trials.

Through this collaboration, CVAF will provide $1.5 million in research funding to support Tolerx's clinical development of TRX518.  CVAF will be eligible to receive milestone payments from Tolerx if TRX518 obtains FDA approval in the future. As part of the alliance, CVAF will provide Tolerx with access to scientific and clinical resources, including the Ludwig Institute's Clinical Trial Management team and the Cancer Vaccine Collaborative, a network of 19 leading medical research institutions around the world with expertise in designing and conducting cutting-edge immunotherapy clinical trials in cancer.  Upon completion of the Phase 1 study, TRX518 may be evaluated in clinical trials in combination with other therapeutic cancer vaccines that could complement TRX518's effect on T cells.

The collaboration established by Tolerx and CVAF is built around the parties' shared belief that anti-GITR antibodies have significant therapeutic potential in cancer.  "Our scientific leadership selected Tolerx's TRX518 antibody as a priority for support because it represents a powerful mechanism for enhancing and sustaining the immune system's attack against cancer cells," said Adam Kolom, Director of the Cancer Vaccine Acceleration Fund of the Cancer Research Institute.  "This partnership between CVAF and Tolerx is an innovative model for how academic investigators, nonprofit medical research organizations, and biopharma companies can leverage each of their unique strengths to expedite the development of important new medicines for patients."

"Based on preclinical results, we believe the clinical potential for TRX518 is promising and are eagerly looking forward to applying CVAF's extensive experience in cancer immunotherapy clinical trials to support Tolerx's efforts," said Jedd Wolchok, MD, PhD, member of the CVAF leadership team and director of immunotherapy clinical trials at Memorial Sloan-Kettering Cancer Center, who will also be the lead clinical investigator in the TRX518 Phase 1 study.

"We are excited that the Cancer Vaccine Acceleration Fund has recognized the potential of TRX518 through their funding of the program, and we value their scientific and clinical expertise that contributed to the design of the Phase 1 study," said Douglas J. Ringler, VMD, President and Chief Executive Officer of Tolerx.  "This collaboration with CVAF will accelerate our efforts to advance TRX518 in human clinical trials, and we are delighted to work with Dr. Wolchok and CVAF's other world-leading experts in immunotherapies for cancer."

Source:

Tolerx, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Finnish researchers discover mechanism behind breast cancer cell reactivation